Alnylam Pharmaceuticals, Inc.
- Home
- Companies
- Alnylam Pharmaceuticals, Inc.
- Products
- OXLUMO lumasiran - Prescription ...
OXLUMO lumasiran - Prescription Medication for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
The first and only FDA-approved prescription medication for the treatment of primary hyperoxaluria type 1 (PH1). OXLUMO is a prescription medicine for the treatment of PH1 to lower oxalate in urine in children and adults.
Most popular related searches
OXLUMO works by reducing oxalate production
Introducing the first and only FDA-approved prescription medication for infants, children and adults with primary hyperoxaluria type 1 (PH1).
OXLUMO targets oxalate overproduction at the source.
- In PH1, the liver produces too much oxalate
- OXLUMO works in the liver to reduce the amount of oxalate being made
- By reducing oxalate, OXLUMO targets the cause of PH1 symptoms
Results of the trial:
53% REDUCTION
Patients on OXLUMO had 53% less oxalate in their urine from the start of treatment at month 6 compared to patients treated with placebo
84% OF PATIENTS
84% of patients on OXLUMO had normal (52%) or close-to-normal (32%) oxalate levels* in their urine at month 6 compared with no patients treated with placebo